APA (7th ed.) Citation

Durma, A. D., Saracyn, M., Kołodziej, M., Jóźwik-Plebanek, K., Dmochowska, B., Mróz, A., . . . Kamiński, G. (2023). Radioligand Therapy with [ 177 Lu]Lu-DOTA-TATE or [ 177 Lu]Lu-DOTA-TATE and [ 90 Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade. Pharmaceuticals (14248247), 16(9), 1205. https://doi.org/10.3390/ph16091205

Chicago Style (17th ed.) Citation

Durma, Adam Daniel, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Adrianna Mróz, Wawrzyniec Żmudzki, and Grzegorz Kamiński. "Radioligand Therapy with [ 177 Lu]Lu-DOTA-TATE or [ 177 Lu]Lu-DOTA-TATE and [ 90 Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade." Pharmaceuticals (14248247) 16, no. 9 (2023): 1205. https://doi.org/10.3390/ph16091205.

MLA (9th ed.) Citation

Durma, Adam Daniel, et al. "Radioligand Therapy with [ 177 Lu]Lu-DOTA-TATE or [ 177 Lu]Lu-DOTA-TATE and [ 90 Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade." Pharmaceuticals (14248247), vol. 16, no. 9, 2023, p. 1205, https://doi.org/10.3390/ph16091205.